Literature DB >> 34977996

Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results.

Bircan Kayaaslan1, Zeynep Oktay2, Imran Hasanoglu3, Ayse Kaya Kalem3, Fatma Eser3, Muge Ayhan2, Rahmet Guner3.   

Abstract

Increasing rates of extended-spectrum beta-lactamase (ESBL) producing E. coli and K. pneumoniae over time made empirical treatment complicated. Knowing local antimicrobial resistance patterns of common pathogens can make it easier to decide on empirical antibiotics. We aimed to investigate the prevalence and risk factors of ESBL positivity of E. coli and K. pneumoniae strains in uncomplicated and complicated pyelonephritis acquired in community and healthcare associations and to evaluate the appropriateness of empirical treatment. Adult patients hospitalized with diagnosis of community-acquired or healthcare-associated uncomplicated/complicated pyelonephritis initiated empirical antimicrobial therapy were included in the study. Appropriateness of empirical treatment at 48-72 h based on culture results and treatment modifications were evaluated. A total of 369 uncomplicated (94) and complicated (275) episodes of pyelonephritis were evaluated. The most common agents were E. coli (71.0%) and K. pneumoniae (17.7%), and the ESBL-production rate was 64.4%, and higher in healthcare-associated pyelonephritis (P 0.013). Being of healthcare-associated infection, previous antibiotic use, and presence of urinary catheters were independent risk factors for ESBL-producing E. coli and K. pneumoniae (P 0.009, < 0.001, and 0.024, respectively). The treatment inappropriateness was mostly associated with use of ceftriaxone (56.3%) (P < 0.001). Treatment has escalated in 41.5% of ceftriaxone-initiated patients, in only 8.8% and 9.5% ertapenem and piperacillin-tazobactam-initiated patients, respectively. ESBL-production rates are quite high even in community-acquired infections. The use of broad-spectrum antibiotics covering ESBL-producing pathogens to increase the appropriateness of empirical treatment and then narrowing treatment based on culture results appears a better and life-saving choice.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Acute pyelonephritis; Antibacterial drug resistance; Appropriateness of therapy; E. coli; Extended-spectrum beta-lactamase (ESBL); Urinary tract infection

Mesh:

Substances:

Year:  2022        PMID: 34977996     DOI: 10.1007/s10096-021-04392-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

Review 2.  Drug-resistant gram-negative uropathogens: A review.

Authors:  Saeed Khoshnood; Mohsen Heidary; Reza Mirnejad; Aghil Bahramian; Mansour Sedighi; Habibollah Mirzaei
Journal:  Biomed Pharmacother       Date:  2017-08-12       Impact factor: 6.529

3.  Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.

Authors:  Hande Arslan; Ozlem Kurt Azap; Onder Ergönül; Funda Timurkaynak
Journal:  J Antimicrob Chemother       Date:  2005-09-20       Impact factor: 5.790

4.  Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.

Authors:  Jesús Rodríguez-Baño; Encarnación Picón; Paloma Gijón; José Ramón Hernández; Maite Ruíz; Carmen Peña; Manuel Almela; Benito Almirante; Fabio Grill; Javier Colomina; Monserrat Giménez; Antonio Oliver; Juan Pablo Horcajada; Gemma Navarro; Ana Coloma; Alvaro Pascual
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

Review 5.  Diagnosis and management of acute pyelonephritis in adults.

Authors:  Kalyanakrishnan Ramakrishnan; Dewey C Scheid
Journal:  Am Fam Physician       Date:  2005-03-01       Impact factor: 3.292

6.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

Review 7.  The epidemiology of urinary tract infection.

Authors:  Betsy Foxman
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

8.  Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.

Authors:  C Peña; C Gudiol; F Tubau; M Saballs; M Pujol; M A Dominguez; L Calatayud; J Ariza; F Gudiol
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

9.  Evaluation of more than one billion outpatient prescriptions and eight-year trend showing a remarkable reduction in antibiotic prescription in Turkey: A success model of governmental interventions at national level.

Authors:  Mesil Aksoy; Fatma Isli; Esma Kadi; Didem Varimli; Hakki Gursoz; Tolga Tolunay; Ates Kara; Serhat Unal; Emine Alp Mese
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-07-01       Impact factor: 2.890

10.  Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe.

Authors:  Ann Versporten; Ganna Bolokhovets; Lilit Ghazaryan; Vafa Abilova; Galina Pyshnik; Tijana Spasojevic; Irma Korinteli; Lul Raka; Baktygul Kambaralieva; Lidija Cizmovic; Angela Carp; Vesela Radonjic; Nargis Maqsudova; Hatice Demet Celik; Marina Payerl-Pal; Hanne Bak Pedersen; Nina Sautenkova; Herman Goossens
Journal:  Lancet Infect Dis       Date:  2014-03-20       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.